Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 13, 2024
Introduction
The
standard
treatment
of
cancer
has
dramatically
improved
with
immune
checkpoint
inhibitors
(ICIs).
Despite
their
proven
advantage,
many
patients
fail
to
exhibit
a
meaningful
and
lasting
response.
beta-adrenergic
signalling
pathway
may
hold
significant
promise
due
its
role
in
promoting
an
immunosuppressive
milieu
within
the
tumour
microenvironment.
Inhibiting
β-adrenergic
could
enhance
ICI
activity;
however,
blocking
this
for
purpose
yielded
conflicting
results.
primary
objective
study
was
evaluate
effect
beta-blocker
use
on
overall
survival
progression-free
during
therapy.
Methods
A
multicentric,
retrospective,
observational
conducted
four
Portuguese
institutions.
Patients
advanced
non-small
cell
lung
treated
ICIs
between
January
2018
December
2019
were
included.
Those
using
beta
blockers
non-oncological
reasons
compared
non-users.
Results
Among
171
included,
36
concomitantly
received
ICIs.
No
increase
found
among
who
took
β-blockers
(HR
0.74,
95%
confidence
interval
(CI)
0.48-1.12,
p
=
0.151),
no
statistically
difference
survival.
An
apparent
trend
observed
towards
better
outcomes
group,
median
9.93
months
group
not
taking
versus
14.90
β-blocker
(p
0.291)
5.37
10.87
0.151).
Nine
(25%)
16
(12%)
non-beta-blocker
progressive
disease-free
at
end
follow-up.
This
two
groups
is
0.047).
Conclusion
Our
evidence
that
effectiveness
immunotherapy.
Using
adrenergic
blockade
modulate
system
shows
promise,
warranting
need
develop
prospective
clinical
studies.
Insights into Imaging,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 17, 2025
Abstract
Objective
This
scoping
review
explores
the
potential
role
of
cancer-staging
chest
CT
scans
in
assessing
cardiovascular
(CV)
risk
cancer
patients.
It
aims
to
evaluate:
(1)
correlation
between
non-gated
and
conventional
Agatston
score
from
cardiac
CT;
(2)
association
coronary
calcium
scores
CV
non-oncological
patients;
(3)
link
assessed
by
events
or
endothelial
damage
Methods
Three
different
searches
were
performed
on
PubMed,
according
three
steps
described
above.
Both
original
articles
systematic
reviews
included.
Results
Many
studies
literature
have
found
a
strong
CTs
gated
CTs.
Various
methodologies,
including
scoring,
ordinal
“extent”
“length”
methods,
been
successfully
adapted
for
use
with
Studies
show
that
scans,
even
those
using
iodinated
contrast,
can
accurately
assess
calcification
predict
risk,
correlations
as
high
r
=
0.94
when
compared
In
oncological
settings,
demonstrated
significant
levels
higher
MACE
overall
mortality.
Conclusions
Radiological
assessment
shows
improving
prediction.
Critical
relevance
statement
Non-gated
detect
patients,
highlighting
need
standardized
radiological
practices
risks
during
routine
follow-up,
thereby
enhancing
radiology’s
comprehensive
care.
Key
Points
Cancer
therapies
improve
outcomes
but
increase
requiring
balanced
management.
Coronary
correlates
scores,
predicting
risk.
Routinely
optimizing
management
Graphical
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
12
Published: Jan. 4, 2023
The
use
of
antibody-drug
conjugates
(ADCs)
is
expanding
in
several
malignancies,
including
urothelial
carcinoma
where
two
these
medications
have
been
approved
for
and
others
remain
under
study.
ADCs
act
by
binding
to
specific
cell
surface
proteins,
delivering
anticancer
agents
directly
the
target
cells.
Preclinical
studies
suggest
that
loss
proteins
alters
sensitivity
therapy
expression
vary
significantly
based
on
tumor
subtype,
prior
therapies
other
characteristics.
However,
biomarkers
predict
treatment
response
not
regularly
included
clinical
trials
clinician
practice.
In
this
review
we
summarize
what
known
about
potential
predictive
UC
discuss
areas
may
improve
patient
care.
Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 13, 2024
Introduction
The
standard
treatment
of
cancer
has
dramatically
improved
with
immune
checkpoint
inhibitors
(ICIs).
Despite
their
proven
advantage,
many
patients
fail
to
exhibit
a
meaningful
and
lasting
response.
beta-adrenergic
signalling
pathway
may
hold
significant
promise
due
its
role
in
promoting
an
immunosuppressive
milieu
within
the
tumour
microenvironment.
Inhibiting
β-adrenergic
could
enhance
ICI
activity;
however,
blocking
this
for
purpose
yielded
conflicting
results.
primary
objective
study
was
evaluate
effect
beta-blocker
use
on
overall
survival
progression-free
during
therapy.
Methods
A
multicentric,
retrospective,
observational
conducted
four
Portuguese
institutions.
Patients
advanced
non-small
cell
lung
treated
ICIs
between
January
2018
December
2019
were
included.
Those
using
beta
blockers
non-oncological
reasons
compared
non-users.
Results
Among
171
included,
36
concomitantly
received
ICIs.
No
increase
found
among
who
took
β-blockers
(HR
0.74,
95%
confidence
interval
(CI)
0.48-1.12,
p
=
0.151),
no
statistically
difference
survival.
An
apparent
trend
observed
towards
better
outcomes
group,
median
9.93
months
group
not
taking
versus
14.90
β-blocker
(p
0.291)
5.37
10.87
0.151).
Nine
(25%)
16
(12%)
non-beta-blocker
progressive
disease-free
at
end
follow-up.
This
two
groups
is
0.047).
Conclusion
Our
evidence
that
effectiveness
immunotherapy.
Using
adrenergic
blockade
modulate
system
shows
promise,
warranting
need
develop
prospective
clinical
studies.
